Trial Agents

EU clinical-trial operational telemetry derived from CTIS authorisations, structured as a trial-by-service-provider-by-function matrix. For each authorised trial the data resolves: whether a CRO or CRO-like provider is engaged, which provider group (IQVIA/Q² Solutions, PPD, Clario/ERT/Bioclinica, ICON, Syneos, Medidata, Parexel), the outsourced functions present across a nine-category service taxonomy (central lab/bioanalysis/PK, imaging/ECG/central reading, patient recruitment/retention/reimbursement, data management/statistics, eClinical/IRT/randomisation, supplies/logistics, monitoring/CTIS-EC support, safety/pharmacovigilance, PRO/eCOA outcomes tech), the country-participation count, site count, planned sample size, design attributes (randomised, adaptive), and recruitment channel (digital, remote support, registry/advocacy). Disease labels are normalised into indication groups. The example slice covers 247 EU neurology Phase III trials with 1,087 country participations.

Open buyer room →

Sample

Brickroad customers

Sample this dataset before you buy it.

Your sourcing agent asks Trial Agents and files the sample in your catalog — private to you.

Start 7-day trialNothing is charged until the trial ends.

Coverage

Universe, instruments and categories.

Industry: Life Sciences Tools & ServicesFinancial Exchanges & Data
Instruments: equities
Categories

Dataset card

Type: not stated
Format: Structured per-trial records aggregated into thematic benchmark reports published as HTML dashboards (percentages, cross-tabulated indication tables, threshold curves); no public API, CSV or bulk export is advertised on the report page, so delivered-data format would need to be scoped with the vendor
Volume: Demonstrated slice: 247 neurology Phase III CTIS trials, 1,087 country participations, 152 CRO-supported trials resolved across a nine-function taxonomy. Catalogue breadth: the reports library spans many indication and phase combinations (plaque psoriasis, gastric cancer, hypertrophic cardiomyopathy, ALS, IgA nephropathy, metastatic colorectal cancer, topical ophthalmic studies, hidradenitis suppurativa, C3 glomerulopathy, Stargardt disease, mitochondrial myopathy and more), so the underlying resolved-trial base plausibly runs to thousands of EU trials against a total CTIS universe in the tens of thousands
Users: N/A at product level — a report/intelligence site with a general enquiry address, no published account or subscriber base; the vendor is small and absent from mainstream business databases, so a plausible reachable audience is tens to a few hundred institutional readers
History: 4 years
Update frequency: not stated
Growth: Active — the report library carries a growing set of parallel indication-and-phase analyses built on the same analytical template, indicating a maintained production pipeline rather than a one-off study
Launched: Request further research — no copyright year, founding date, funding event, registration entry or dated publication appears anywhere in the captured content, and the company is absent from the mainstream business databases searched, so no dating signal of any kind was available to bound the launch
Delivery: not stated
Entity mapping: not stated
Sample: not stated
Point-in-time: not stated
Licence: not stated

supplier index read from their site